Brought to you by 
GSK acquires dermatology company Stiefel for $3.6bn
15 May 2009
Executive Summary
About a month after rumors surfaced that it was up for sale, private skin care player Stiefel Laboratories announced it will be acquired by GlaxoSmithKline for $2.9bn cash and the assumption of $400mm in debt. Stiefel shareholders are entitled to $300mm in performance-based earn-outs.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK acquires dermatology company Stiefel for $3.6bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice